NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Psychedelic Research Recap: August 2026
August 2026's psychedelic research recap on clinical trials, regulated services, healthy-volunteer studies, brain imaging, biomarkers and treatment delivery.
Higher signal diversity, network dysregulation, and increased well-being under DMT administration: An EEG study
This EEG study (n=13) compared intravenous DMT with saline placebo in healthy participants. DMT altered brain-signal complexity and reduced connectivity, while complexity and EEG measures interpreted as arousal and we...
Temporal structure of psychedelic EEG: statistical unit, dose, and receptor mechanism in multi-scale dynamics
This preprint reanalysed public EEG datasets for psilocybin microdosing (n=31), ketamine (n=8) and DMT (n=6). Analyses treating participants as the statistical unit found no significant microdose effect, while both ke...
Higher signal diversity, network dysregulation, and increased well-being under DMT administration: An EEG study
This EEG study (n=13) compared intravenous DMT with saline placebo in healthy participants. DMT altered brain-signal complexity and reduced connectivity, while complexity and EEG measures interpreted as arousal and we...
The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
This Phase IIa randomised, double-blind crossover trial (n=11) tested the mGlu2/3 antagonist TS-161 against placebo for treatment-resistant depression. The study stopped early because of low recruitment and found no a...
The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
This Phase IIa randomised, double-blind crossover trial (n=11) tested the mGlu2/3 antagonist TS-161 against placebo for treatment-resistant depression. The study stopped early because of low recruitment and found no a...
Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study
This observational preprint (n=30) followed people with treatment-resistant depression through eight intranasal esketamine treatments. Higher baseline metabolic burden was associated with greater improvement in depres...
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial
This multisite open-label study (n=69) examined intravenous racemic ketamine (35 mg/70 kg) given in three infusions to adults with treatment-resistant depression, finding that depressive symptoms improved and 54% reac...
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial
This multisite open-label study (n=69) examined intravenous racemic ketamine (35 mg/70 kg) given in three infusions to adults with treatment-resistant depression, finding that depressive symptoms improved and 54% reac...
A supervised human trial found oral psilocin and psilocybin produced nearly indistinguishable effects, while oral psilocin caused fewer adverse side effects and sublingual psilocin was milder and shorter-lived.
The first direct human comparison since the 1960s examined psilocin and psilocybin across onset, intensity, duration and deep psychological effects. Oral psilocin had a lower overall burden of mostly mild adverse effe...
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2…
A federal report encourages states to prepare for FDA approval of psychedelics; Could THC help with the psychedelic blinding problem?
Plus: Ketamine seized at the UK border hits record high; an Arizona ibogaine trial; Study reveals cell signaling that differentiates hallucinogens and non-hallucinogens
7 Questions I'm Obsessed With About Psychedelics Right Now
Welcome to The Psychedelic Blog. An independent media platform covering drugs, altered states & the culture surrounding them.
Is “Gas Station Molly” the Next Big Grey Market Drug?
It feels like MDMA, skips the comedown, and it's already on head shop shelves. But is it legal? [...] Read More... The post Is “Gas Station Molly” the Next Big Grey Market Drug? appeared first on DoubleBlind Mag.
New Zealand approves use of party drug MDMA to treat trauma
Two psychiatrists in New Zealand won approval Friday to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder.